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Objective: The aim of the study was to analyse the psychometric properties of the EQ-5D in patients with social phobia.
Methods: We used a sample of 445 patients with social phobia with five measurement points over a 30 month period.
The discriminative ability of the EQ-5D was analysed by comparing the patients’ responses with the general population
and between different disease severity levels. For test-retest reliability we assessed the level of agreement in patients’
responses over time, when there was no change in the Liebowitz Social Anxiety Scale (LSAS). Construct validity was
analysed by identifying correlations of the EQ-5D with more specific instruments. For responsiveness we compared the
means of EQ VAS/EQ-5D index anchored on improved (deteriorated) health status and computed effect sizes as well as
a receiver operating characteristic (ROC) curve.
Results: Compared to the general population, patients with social phobia reported more problems in the dimensions
“usual activities”, “pain/discomfort”, and “anxiety/depression” and less problems in “mobility” and “self-care”. The EQ-5D
was able to distinguish between different disease severity levels. The test-retest reliability was moderate (intraclass
correlation coefficient > 0.6). Correlations between the EQ-5D and other instruments were mostly small except for
correlations with Beck Depression Inventory. The EQ-5D index seemed to be more responsive than the EQ VAS, but
with only medium effect sizes (0.5 < effect size < 0.8) in the British EQ-5D index and only significant in patients
with improved health status. The ROC analysis revealed no significant results.
Conclusions: The EQ-5D was moderately reliable and responsive in patients with improved health status. Construct
validity was limited.
Trial registration: Current controlled trials ISRCTN53517394
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The EQ-5D is a generic, preference-based index score
instrument to measure health related quality of life
(HRQOL). The index score is used to compute quality-
adjusted life years (QALYs) in cost-utility analysis. Due
to scarce resources, economic evaluations are import-
ant tools for decision-making on health care resource* Correspondence: mi.sonntag@uke.de
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reproduction in any medium, provided the orallocation. Therefore, the instrument used to measure
health effects should show good psychometric properties.
The EQ-5D has demonstrated its psychometric properties
in various diseases and disorders (e.g. inflammatory bowel
disease [1], stroke patients [2], schizophrenic, schizotypal,
and delusional disorders [3], anxiety disorders [4]). Al-
though the EQ-5D has been used in patients with social
phobia [5-8], no validation of the EQ-5D in this patient
group has been conducted so far.
Social phobia (SP), also known as social anxiety disorder,
is the second most frequent anxiety-mood disorder with a
12-month prevalence rate of 1.9% in Europe [9]. The mainl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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embarrassed in social or performance situations as well
as avoidance of such situations (ICD-10 [10], DSM-IV
[11]). The fears may be associated with specific situations
like public-speaking (“discrete” or “specific” SP) or with
social interactions in general (“generalized” SP). SP has an
early onset [12], tends to become chronic [13], and is often
accompanied with other psychiatric disorders (such as
bipolar disorder, substance abuse disorder, or personality
disorder) [14].
The aim of this study was to test the psychometric
properties of the EQ-5D in patients with SP. In particular,
we analysed the discriminative ability (ability to discrimin-
ate between different health states of SP), the test-retest
reliability (ability to repeat the similar results when the
underlying construct is unchanged), the construct validity
(ability to measure adequately the underlying construct),
and the responsiveness of the EQ-5D (ability to detect
changes given a change in the underlying construct).
Methods
Subjects and study design
This study is part of a multicenter randomized controlled
trial comparing cognitive behavioural therapy and psycho-
dynamic short therapy for SP (ISRCTN53517394). The
trial is part of the Social Phobia Psychotherapy Research
Network (SOPHO-NET) [15]. Design and results of the
trial have been reported elsewhere [16].
Patients were recruited in five outpatient university
clinics across Germany (Bochum, Dresden, Göttingen, Jena,
and Mainz), from April 2007 until April 2009. The patient
sample can be considered as clinically representative [16].
Inclusion criteria were: (I) diagnosis of SP according to
the Structured Clinical Interview for DSM-IV [17] and
a Liebowitz Social Anxiety Scale (LSAS) score higher than
30 points [18]; (II) age between 18 and 70; (III) SP being
the primary diagnosis based on the severity disorder
classification of the Anxiety Disorders Interview Sched-
ule [19]. Exclusion criteria were: (I) psychotic and acute
substance-related disorders; cluster A and B personality
disorders; prominent risk of self-harm; (II) organic mental
disorders; (III) severe medical conditions; (IV) concurrent
psychotherapeutic or psychopharmacological treatment [16].
495 patients were randomized to one of the therapy
groups (n = 416) or a waiting list group (n = 79). After
treatments were completed in the therapy groups, waiting
list patients were also randomized to one of the therapy
groups and treated as well. Data were collected pre-
treatment (T0, n = 495) and post-treatment (T1, n = 364),
as well as 6 months (T2, n = 321), 12 months (T3, n = 262),
and 24 months (T4, n = 183) after completed treatment
(T1). The time interval between T0 and T1 was minimum
6 months but varied due to delays in administrative proce-
dures, vacations, or illness of patients or therapists.Due to missing data in EQ-5D questionnaires, we used a
subsample of n = 445 (t0), n = 329 (t1), n = 288 (t2), n = 244
(t3) and n = 166 (t4) for our analyses.
Measures
EQ-5D
The EQ-5D contains three concepts of expressing HRQOL
[20]: (I) The patient-reported “EQ-5D descriptive system”
has five items, so called “dimensions” (“mobility”, “self-care”,
“usual activities”, “pain/discomfort”, “anxiety/depression”).
Each of them is recorded with an ordinal three level code
(1: “no problems”, 2: “moderate problems”, 3: “severe prob-
lems”), resulting in 243 (35) possible health states. These
can be expressed as 5-digit codes (e.g. “11233” refers to no
problems in “mobility” and “self-care”, moderate problems
in “usual activities”, and severe problems in “pain/discom-
fort” and “anxiety/depression”).
(II) The 5-digit code can be transformed into a utility
weight, the so called EQ-5D index. The EQ-5D index is
based on a valuation of health states by the general
population – indicating the preferences from the general
population’s perspective. The EQ-5D index ranges to a
maximum utility weight of 1 (full health). Death is valued
with 0. The worst possible health state (“33333”) is -0.21
for the German EQ-5D index [21] and -0.59 for the British
EQ-5D index [22], indicating health states valued worse
than death. Both EQ-5D index scores were computed by
regression analysis leading to a different valuation of the
same health state. In our study we labelled the German
EQ-5D index score “EQ-5D index-G” and the British EQ-
5D index score “EQ-5D index-UK”. Although we analysed
a German patient sample, we used both EQ-5D indexes
(being aware of the limited comparability between both
populations). The EQ-5D index-G was based on a small
population sample (nGerman = 334 vs. nUK = 2997) and must
thus be considered less precise for statistical reasons. The
German EQ-5D index scores for all 243 EQ-5D health
states were estimated from a sample of 36 health states
using a regression model. In contrast to the British EQ-
5D index, the German EQ-5D index is insensitive to a
change from level 1 (“no problems”) to level 2 (“moderate
problems”) in the dimension “anxiety/depression” due to
omitted regression coefficients. Therefore, the EQ-5D
index-G scores must be considered preliminary.
(III) Patients are asked to rate their current health state
on a visual analogue scale (EQ VAS) ranging from 0 (worst
imaginable health state) to 100 (best imaginable health
state). The EQ VAS represents the value of HRQOL from
patients’ perspective.
Liebowitz social anxiety scale (LSAS)
The LSAS is a 24-item clinician-administered SP screening
instrument, measuring anxiety and avoidance [23]. Both
subscales (“LSAS avoidance score” and “LSAS anxiety
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to 144 (“LSAS total score”). LSAS total scores below 30
indicate remission of SP, scores between 30 and 59
indicate specific SP, and scores above 60 indicate gener-
alised SP [18].
Social phobia and anxiety inventory (SPAI)
The SPAI is a self-reported SP screening instrument,
measuring the disease severity level of SP [24]. The German
version of SPAI contains 22 items [25]. Each item ranges
from “never” (coded as 0) to “always” (coded as 6), leading
to a 7 point Likert scale. The SPAI score as the mean
of all 22 items ranges from 0 to 6 with an increasing
severity level of SP.
Beck Depression Inventory (BDI)
The BDI is a screening instrument for depression [26].
Patients are asked to rate their feelings throughout the
last week and today on 21 items. The items range from
0 to 3 with an increasing disease severity level and are
added up to a total score ranging from 0 to 63.
Analysis
For statistical analysis, we collapsed “moderate problems”
and “severe problems” of the EQ-5D descriptive system
into one category “problems” (except for analysing dis-
criminative ability related to the general population), be-
cause the number of patients indicating “severe problems”
was small.
Discriminative ability reflects the ability of an instrument
to discriminate between different health states [27]. We
assumed that the EQ-5D discriminates between patients
with SP and the general population and between different
levels of disease severity in patients with SP. For the
comparison with the general population, we used EQ-5D
data from a representative survey (n = 3552) in Germany
[28] adjusted for age and gender due to the young age
in the patient sample. To distinguish between disease
severity levels, we grouped patients into quartiles of the
LSAS total score and its both subscales, and alternatively,
into patients with specific SP (30 to 59 LSAS total score)
and generalised SP (≥ 60 LSAS total score). We tested
for significance by using χ2-test and Fisher’s exact test
(EQ-5D descriptive system) and Mann-Whitney-U-test
(EQ-5D index and EQ VAS).
Test-retest reliability reflects the ability of an instrument
to produce similar results if the underlying construct
has not changed [29,30]. The LSAS total score was used
as clinical anchor. We assumed that the score of both
EQ-5D indexes and the EQ VAS stay constant if the
change in LSAS total score stays within range of 0 ± 0.5
standard deviations (baseline) which has been recom-
mended by [31,32], corresponding to 11 LSAS total score
points. Additionally, we split the “no change” group intopatients with and without social phobia (< 30 LSAS total
score points at both time points).
For the EQ-5D index scores and the EQ VAS score, we
analysed test-retest reliability using the intraclass correl-
ation coefficient (ICC) with a two way mixed model. We
considered an ICC ≥ 0.7 as large [30].
Construct validity reflects how appropriately the instru-
ment refers to the underlying construct [30]. We assumed
that there is an association between the EQ-5D and
instruments of psychopathology used as the underlying
construct (LSAS total score, LSAS avoidance score, LSAS
anxiety score, SPAI score, SPAI No. 22 score, and BDI
score). Since both EQ-5D index scores and the EQ VAS
score did not follow a normal distribution, we computed
the non-parametric Spearman rank correlation coefficient
(rs) for both EQ-5D index scores and the EQ VAS score.
We defined a correlation as small for 0.1 ≤ |rs| < 0.3, mod-
erate for 0.3 ≤ |rs| < 0.5, and large for |rs| ≥ 0.5 [33].
Responsiveness reflects the ability of an instrument to
change, given a change in the underlying construct [30].
Again, the LSAS total score was used as clinical anchor.
We assumed that both EQ-5D indexes and the EQ VAS
score change over time if the LSAS total score has changed.
We defined a relevant change as more than ± 0.5 standard
deviations (baseline) which has been recommended by
[31,32], corresponding to 11 LSAS total score points. The
responsiveness can be assessed inmany different ways [34-38].
In our analysis we used the paired t-test statistics and com-
puted the effect size (ES) to assess the association of change in
both EQ-5D indexes and the EQ VAS with the change in the
LSAS total score. According to Cohen, we defined scores of
ES as trivial from ≥ |0.1| to < |0.2|, as small from ≥ |0.2| to < |
0.5|, as medium from ≥ |0.5| to <|0.8|, and as large ≥ |0.8| [33].
Alternatively, we calculated the area under curve (AUC) of the
receiver operating characteristic (ROC) curve. An AUC of 0.5
indicates that the instrument randomly detects the true
change of patients’ health status. The closer the AUC equals
1.0 the more the instrument is able to detect the true change
of patients’ health status [39,40].
As we tested several hypotheses, a Bonferroni correction
for the level of significance was computed. Six different
instruments were used for analysing construct validity,
leading to a corrected level of significance of α = 0.05/6 =
0.0083. Ten different chronological comparison-pairs were
used for analysing reliability and responsiveness. Thus, the
level of significance was defined as α = 0.05/10 = 0.005.
Statistical analyses were conducted using Statistical




Patient characteristics at baseline are shown in Table 1.
Mean age was 35.1 years (SD: 12.1). Most of the partici-










Living situation: n (%)
Alone 148 (33.3)
With spouse/partner 183 (41.1)
With relatives 72 (16.2)






Age: mean (SD) 35.1 (12.1)
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their spouse/partner (41.1%), and had finished the second-
ary school (68.5%).
EQ-5D scores
In the EQ-5D descriptive system, 81.8% of patients re-
ported problems in at least one dimension. Specifically,
75.4% of patients reported at least moderate problems in
the dimension “anxiety/depression”, followed by “pain/
discomfort” (35.1%), “usual activities” (27.2%), and “mobility”
(5.4%). In contrast, no patient reported problems in the
dimension “self-care”. The health state 11112 was the
most frequently reported health state (30.3%), indicating
moderate problems in the dimension “anxiety/depression”,
followed by 11111 (18.2%), and 11122 (16.0%). While the
mean EQ-5D index-UK was 0.78 (SD: 0.18), the mean
EQ-5D index-G was 0.92 (SD: 0.13). The mean EQ VAS
score was 75.21 (SD: 16.8) (Table 2).
Scores of instruments of psychopathology
Mean LSAS total score was 72.2 (SD: 22.0), indicating
marked SP (in detail see Table 2). Mean LSAS avoidance
score was 32.8 (SD: 12.1) and LSAS anxiety score was
39.3 (SD: 10.9). The SPAI score displayed a mean of 4.1
(SD: 0.87), indicating moderate SP. Mean of SPAI No. 22
score was 3.2 (SD: 1.04), indicating moderate physiological
reactions in social situations. The mean BDI score was
14.2 (SD: 9.1), indicating mild depression.Discriminative ability
Compared to the general population, patients with SP re-
ported significantly less problems in the EQ-5D dimensions
“mobility” and “self-care” but significantly more problems in
the EQ-5D dimensions “usual activities”, “pain/discomfort”,
and “anxiety/depression” (p < 0.05, see Figure 1).
With increasing disease severity level (according to
LSAS-quartiles), the proportion of patients indicating
problems continuously increased in the EQ-5D dimensions
“usual activities” and “anxiety/depression”, and the EQ-5D
index-UK and the EQ VAS score continuously decreased,
respectively (Table 3). However, most of these differences
were not significant except for the EQ-5D index-UK for
which two of three pair-wise comparisons between LSAS
quartiles were significant.
The analysis of LSAS avoidance score and LSAS anxiety
score showed similar patterns for the EQ-5D dimensions.
However, we could not find any significant differences in
the EQ-5D index scores and the EQ VAS except for both
EQ-5D indexes between the third (LSAS anxiety score
range from 38 to 47) and fourth quartile (above 48 LSAS
anxiety score points) in the LSAS anxiety score (results
not displayed).
When comparing patients with specific and generalised
SP, patients with generalised SP reported significantly
more problems in the EQ-5D dimensions “usual activities”
and “anxiety/depression”, and had significantly lower EQ-
5D index scores and EQ VAS score compared to patients
with specific SP.Test-retest reliability
Due to five measurements, we could test the test-retest
reliability for 10 different chronologically paired compari-
sons. For patients with no health status change, the ICC of
the EQ VAS score and of the EQ-5D index-G was mostly
about 0.6, indicating moderate correlation (Table 4). The
ICC of the EQ-5D index-UK was low regarding compari-
sons including baseline (t0), whereas the ICC was mostly
large in all other chronological comparisons (ICC > 0.7).
The EQ-5D index-UK showed slightly higher ICCs com-
pared to the EQ-5D index-G. Thereby, the group of patients
with SP had predominantly higher ICCs in comparison to
the group of patients without SP.Construct validity
Both EQ-5D indexes and the EQ VAS score were sig-
nificantly correlated with the reference instruments,
but the correlations were only small (|rs| ≤ 0.27; Table 5)
aside from a moderate correlation with the BDI score
(|rs| ≥ 0.44). Additionally, the SPAI score showed a slightly
moderate correlation with both EQ-5D index scores
(|rs| ≥ 0.31).
Table 2 Descriptive statistics of the EQ VAS score, the EQ-5D index-G, EQ-5D index-UK, and the comparators at
baseline
Measures Possible range of
score (worst-best)
Na Score
Mean (SD) Median (range)
EQ VAS score 0 - 100 438 75.2 (16.8) 80 (25 - 100)
EQ-5D index-G −0.21 - 1.000 443 0.920 (0.135) 0.999 (0.361 - 1.000)
EQ-5D index-UK −0.59 - 1.000 443 0.785 (0.178) 0.814 (0.186 - 1.000)
LSAS total score 144 - 0 445 72.2 (22.0) 70.0 (10 - 127)
LSAS anxiety score 72 - 0 445 39.3 (10.9) 38.0 (10 - 67)
LSAS avoidance score 72 - 0 445 32.8 (12.1) 32.0 (0 - 65)
SPAI score 6 - 0 437 4.1 (0.9) 4.0 (1 - 6)
SPAI No. 22 score 6 - 0 421 3.2 (1.0) 3.2 (0 - 6)
BDI score 63 - 0 434 14.2 (9.1) 13.0 (0 - 42)
aNumber of observations varied due to missing values; BDI: Beck Depression Inventory; LSAS: Liebowitz Social Anxiety Scale; SPAI: Social Phobia and
Anxiety Inventory.
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For patients reporting an improvement in their health
status on the LSAS total score, both EQ-5D indexes
and the EQ VAS score showed significant effect sizes
only for comparisons to baseline (t0). The effect sizes
were mostly small (ES = 0.2 to 0.5; Table 6). The EQ-5D
index-UK was the most responsive score (ES > 0.5). For
patients with deterioration in their health status on the
LSAS total score, we found no significant effect sizes at
all (results not displayed).Figure 1 Comparison of EQ-5D dimensions between patient sample (
population from [28]. Respondents of the general population were adjuste
(n = 444) and two missing values in “anxiety/depression” (n = 443) in patienIn the ROC analysis, the area under curve was pre-
dominantly between 0.5 and 0.6, irrespective of the
direction of change of patients’ health status (results
not displayed). Furthermore, the area under curve in
all time comparisons was not significantly different from
the area under the diagonal.
Discussion
While the psychometric properties of the EQ-5D were
analysed in many other diseases and disorders, this studyn = 445) and general population (n = 3137). Data of the general
d to age and gender. There were one missing value in “usual activities”
ts with social phobia.
Table 3 Patients reporting problems in the EQ-5D dimensions (%) and mean EQ VAS score/EQ-5D index scores by


















30 – 55 110 3 0 16 29* 59* 79 0.944* 0.838*
56 – 70 113 6 0 19* 43* 77 78 0.928 0.795
71 – 87 111a 4 0 31 29 79 74 0.928* 0.788*
≥88 111b 9 0 42 39 86 70 0.879 0.718
Specific SP 137 3 0 16* 34 64* 79* 0.940* 0.828*
Generalised SP 308c 7 0 32 36 81 74 0.911 0.766
*p ≤ 0.05 regarding differences to the next group of disease severity; SP: social phobia.
aone missing value in “usual activities” and “anxiety/depression”.
bone missing value in “anxiety/depression”.
cone missing value in “usual activities” and two missing values in “anxiety/depression”.
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with SP.
The lack of precision of the German EQ-5D index in
the dimension anxiety/depression, resulting from the
small population sample used to derive the German
EQ-5D index, strongly hampers its application in men-
tally ill patients. Therefore, we also used the British
EQ-5D index although British health state preferences
may be different from German preferences and may
possibly bias our results.
Discriminative ability
The EQ-5D showed good discriminative ability between
the general population and patients with SP. With respect
to the EQ-5D dimensions “usual activity”, “pain/discom-
fort”, and “anxiety/depression”, patients with SP reported
significantly more problems than the gender and age
adjusted general population which can be attributed to the
characteristics of SP such as the fear of social interactions.Table 4 Reliability of the EQ VAS score and EQ-5D index scor
Time Number of patients EQ VAS score
All SP No SP All SP N
t0 - t1 ( 6 m) 67 67 0.60** -
t0 - t2 (12 m) 44 44 0.53** -
t0 - t3 (18 m) 30 30 0.71** -
t0 - t4 (30 m) 21 21 0.65 -
t1 - t2 ( 6 m) 181 106 75 0.66** 0.68* 0
t1 - t3 (12 m) 145 79 66 0.66** 0.68* 0
t1 - t4 (24 m) 92 49 43 0.60** 0.65*
t2 - t3 ( 6 m) 169 94 75 0.83** 0.81* 0
t2 - t4 (18 m) 104 54 50 0.60** 0.58* 0
t3 - t4 (12 m) 111 60 51 0.72** 0.68* 0
LSAS: Liebowitz Social Anxiety Scale; m: months; SP: Social Phobia. ** p ≤ 0.005; * p
0.5 SD. Patients without social phobia had a LSAS total score <30 in both time poinWith respect to the EQ-5D dimensions “mobility” and
“self-care”, patients with SP reported significantly less
problems than the gender and age adjusted general
population. Therefore, one may argue that these EQ-
5D dimensions may not have a substantial effect on
HRQOL in patients with SP. Problems in mobility may
not refer to SP but rather to other co-morbidities.
As there are no validated cut-offs for the LSAS total
score available, we used the following two definitions of
cut-offs for the LSAS: firstly, we used quartiles, reflecting
the severity of SP, secondly we distinguished between
specific and generalized SP, reflecting two diagnostic
categories.
Using quartiles, the EQ-5D indexes were only able to
discriminate between the first and second quartile and
between the third and fourth quartile of the LSAS total
score scale, whereas the EQ VAS score was not able to
significantly discriminate at all. The limited discriminative
ability between the second and third quartile may bees anchored by no change of the LSAS total score
Intraclass correlation coefficient
EQ-5D index-G EQ-5D index-UK





.58* 0.61** 0.74* 0.17 0.74** 0.78* 0.52*
.52* 0.47** 0.56* 0.06 0.65** 0.65* 0.38
0.32 0.74** 0.77* 0.32 0.73** 0.73* 0.46
.82* 0.73** 0.72* 0.58* 0.79** 0.78* 0.69*
.59* 0.51** 0.50* 0.49* 0.62** 0.62* 0.55*
.75* 0.67** 0.65* 0.61* 0.78** 0.78* 0.60*
≤ 0.008. No change of the LSAS total score was defined within the range of 0 ±
ts. In t0 there were no patients < 30 LSAS total score points.
Table 5 Correlation between EQ VAS score, EQ-5D index
scores, and scores of other instruments at baseline
Correlation coefficients
EQ VAS score EQ-5D index-G EQ-5D index-UK
LSAS
_total score −0.20* −0.22* −0.24*
_anxiety −0.21* −0.23* −0.25*
_avoidance −0.17* −0.19* −0.21*
BDI score −0.44* −0.44* −0.47*
SPAI score −0.24* −0.31* −0.33*
SPAI No. 22 score −0.18* −0.16* −0.17*
BDI: Beck Depression Inventory; LSAS: Liebowitz Social Anxiety Scale; SPAI:
Social Phobia and Anxiety Inventory.
Spearman rank correlation coefficient; * p ≤ 0.001; due to missing values the
range of observation varied between 410 ≤ n ≤ 438.
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patients with severe specific SP and patients with less
severe generalised SP.
The EQ-5D was able to discriminate between patients
with specific and generalized SP. These findings indicate
that the EQ-5D can differentiate to some extent between
patients with different disease severity levels of SP depend-
ing on the definition of cut-offs of the disease specific
instrument.
The results indicated ceiling effects in both EQ-5D
index scores and the EQ-VAS score. The ceiling effects
result to some extent from the young study sample in
which most of the patients had no problems in self-care
and mobility. SP may be in general more related to the
dimensions “anxiety/depression” and “usual activities” of
the EQ-5D. However, the latter dimensions may not dis-
tinguish well between patients with mild SP. Thus, some
patients tend to report no problems. Both reasons lead
to an upward shift of the EQ-5D index scores.
Taken together, we conclude that there is limited
evidence that the EQ-5D has discriminative ability in
patients with SP.
Test-retest reliability
We found moderate to large ICCs of the EQ VAS score and
EQ-5D index scores in most of the pairwise comparisons.Table 6 Responsiveness of EQ VAS score and EQ-5D index sco
Imp
|Mean difference| (SDmean difference)
Time interval n EQ VAS score EQ-5D index-G EQ-5D inde
t0-t1 ( 6 m) 235 .073 (.18
t0-t2 (12 m) 214 3.79 (16.7) .026 (.132) .083 (.17
t0-t3 (18 m) 189 4.51 (16.8) .038 (.123) .107 (.17
t0-t4 (30 m) 129 .091 (.19
LSAS: Liebowitz Social Anxiety Scale; m: months. * p ≤ 0.005. A change of the LSAS
displayed only significant results.Thereby, the EQ-5D index-UK showed slightly higher
ICCs than both other scores. When comparing patients
with and without SP, we found that patients with SP
had higher ICCs compared to patients without SP.
Thus, the EQ-5D seems to be reliable, in particular in
patients with SP.Construct validity
We identified only small negative Spearman rank correl-
ation coefficients related to the EQ VAS score and the
EQ-5D index scores, except for the BDI score and partly
for the SPAI score, in which the correlation was moder-
ate. One may argue that both the LSAS total score (and
its sub-scores) and SPAI No. 22 score measure different
aspects of HRQOL than the EQ-5D. The BDI score and
the SPAI score cover some aspects of HRQOL measured
by the EQ-5D, namely, the “anxiety/depression” dimension
of the EQ-5D. Due to this discrepancy, we may explain this
low construct validity of the EQ-5D.Responsiveness
We found significant small to medium effect sizes of the
EQ VAS score and the EQ-5D index scores in patients
with an improved LSAS total score referring to the base-
line. In other chronological comparisons we found no
significant effect sizes. We assume that treatment effects
mainly led to these different effect sizes. Due to therapy,
patients improved their health status, leading to a decrease
in the LSAS total score. These improvements in health
status may be largest compared to baseline and may flat-
ten over time. This indicates that the EQ VAS score and
the EQ-5D index scores respond to improvements of
health in patients with SP if the improvement is substan-
tial. The EQ-5D may have problems to detect patients
with deterioration in their health status, but in our study
the sample of patients reporting worse health states was
too small to draw any conclusions.
In the ROC analysis, we did not find any significant
results. It is possible that the application of ROC curves
may be limited in this study due to the small sample
size of patients reporting a relevant change.res anchored by LSAS total score change
rovement of health status
Effect size
x-UK EQ VAS score EQ-5D index-G EQ-5D index-UK
3) 0.44 *
3) 0.24 * 0.23 * 0.50 *
5) 0.26 * 0.30 * 0.64 *
8) 0.53 *
total score was defined by more than 0 ± 0.5 SD (baseline). For clarity, we
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We found two articles assessing the psychometric prop-
erties of the EQ-5D in anxiety disorders. Lamers et al.
[8] analysed discriminative ability and responsiveness of
the EQ-5D in a sample of 616 patients with mood and/
or anxiety disorders whereas König et al. [4] assessed
construct validity and responsiveness in a sample of 389
patients with anxiety disorders.
Regarding the discriminative ability, in the study of
Lamers et al. (2006) the EQ-5D index-UK was able
to discriminate between different severity subgroups
(anchored by the SCL-90 score) except for patients
with very severe mood and/or anxiety disorders. In
our study, the discriminative ability of the EQ-5D was
good in patients with mild and very severe health
states. The observed difference in the discriminative
ability of the EQ-5D in both disorders may be due to
the different properties of the clinical anchors used in
the two studies.
Regarding the construct validity, in the study of König
et al. (2010) the EQ-5D index-UK and EQ VAS showed
large correlations with the BDI scores (rs = 0.59 and
rs = 0.54), indicating good construct validity. In our study,
the correlation between the BDI scores and the EQ-5D
index-UK and EQ VAS, respectively, was similar (rs = 0.47
and rs = 0.44).
Regarding the responsiveness, in the study of Lamers
et al. (2006) the responsiveness of the EQ-5D was small
(standardised response mean: 0.47). In the study of König
et al. (2008) the EQ-5D index-UK showed large effect sizes
(0.99) and medium standardised response mean (0.54) in
patients reporting worse health status, whereas ES and
SRM of the EQ-5D index-UK and EQ VAS were trivial to
small in patients with an improved health status. As both
cited studies used different clinical anchors for a relevant
change compared to our study, the comparability may
be limited. Notwithstanding, the responsiveness of the
EQ-5D seemed to be similar in patients with an improved
health status.
Strengths and limitations
Our study was based on a large multicenter patient
sample resulting in good statistical power. With five
different measurements in time we could assess very well
the reliability and the responsiveness of the EQ-5D.
However, our study has several limitations. First of all,
we could only test the psychometric properties of the
EQ-5D with disease specific instruments. Therefore, there
may be some limitations in generalisation of our results.
Notwithstanding, we could find overall at least moderate
psychometric properties indicating that the EQ-5D may
be a valid instrument to measure HRQOL of patients with
SP. Another limitation of our study was that we had no
validated instrument to assess the psychometric propertiesin the EQ-5D dimension “pain/discomfort”. Thus, we used
only a not pain specific instrument (SPAI No. 22 score),
indicating just small correlation coefficients in case of
both EQ-5D indexes and the EQ VAS score.
Implications for further research
We suggest three further research topics: (i) The construct
validity of the EQ-5D dimension “pain/discomfort” should
be reanalysed with a validated instrument. (ii) The EQ-5D
should be compared with other generic HRQOL instru-
ments (e.g. SF-36). (iii) The responsiveness in patients
with worsened health states should be analysed.
Conclusion
The EQ-5D seems to be a moderately valid instrument
to measure HRQOL in patients with SP. In detail, our
study showed a reasonable discriminative ability and
reliability. The responsiveness was good as long as the
improvement in patients’ health status was clinically
substantial. In cases with patients reporting a worse
health status, we could not find reasonable results due
to small number of patients. Further studies should val-
idate the EQ-5D with another instrument of HRQOL
(e.g. SF-36) and for patients reporting a declined health
status. Overall, the EQ-5D may be suitable for application
in patients with SP.
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